<DOC>
	<DOCNO>NCT02667223</DOCNO>
	<brief_summary>This Phase 1 , open-label , single-dose , randomize , dose escalation study healthy hypercholesterolemic subject . Each subject receive 1 5 treatment single subcutaneous injection . Subjects remain confined research clinic approximately 2 day . After discharge , subject return research clinic 15 time 12 week .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Study Bococizumab Alone When Combined With Recombinant Human Hyaluronidase</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Healthy hypercholesterolemic subject age 18 65 year . Healthy subject must fast LDLC &gt; /= 70 &lt; /= 190 mg/dL two qualify visit . Hypercholesterolemic subject must stable daily dose statin least 45 day dose fast LDLC must &gt; /= 70 mg/dL . Use prescription nonprescription drug within 7 day 5 halflives ( whichever ) long prior first dose study medication . For hypercholesterolemic subject use statin class medication allow . Prior exposure bococizumab ( also know PF04950615 RN316 ) investigational PCSK9 inhibitor . Treatment monoclonal antibody within 6 month 5 halflives ( whichever longer ) dosing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>RN316</keyword>
	<keyword>recombinant human hyaluronidase</keyword>
</DOC>